Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus
Primary Purpose
Obesity; Endocrine; Diabetes Type 2
Status
Completed
Phase
Early Phase 1
Locations
Egypt
Study Type
Interventional
Intervention
Montelukast 10mg
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Obesity; Endocrine; Diabetes Type 2
Eligibility Criteria
Inclusion Criteria:
- type 2 diabetic patients who had body mass index (BMI) ≥ 30 kg/m2 , were treated with metformin alone and had ages ranging from 18 to 60 years.
Exclusion Criteria:
- patients who had any other inflammatory disease
- patients with cardiovascular,
- patients with asthma
- patients with severe hepatic
- patients with renal disease,
- patients with epilepsy
- pregnant or lactating females.
Sites / Locations
- Faculty of Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Control group
Montelukast group
Arm Description
50 patients will receive metformin up to 2000mg/daily (Control group)
50 patients will receive a combination of metformin up to 2000 mg/daily and montelukast (10 mg /day).
Outcomes
Primary Outcome Measures
Change in HbA1c
HbA1c
Percent change in body weight
Body Weight
BMI
body mass index
Visceral Adiposity Index
visceral fat
Secondary Outcome Measures
Adiponectin
Serum level of adiponectin
TNF-α
Serum level of Tumor necrosis factor alpha (TNF-α)
IL-6
Serum level of interleukin-6 (IL-6)
leukotriene B4
Serum level of leukotriene B4 (LTB4)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04075110
Brief Title
Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus
Official Title
Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
July 1, 2019 (Actual)
Primary Completion Date
June 1, 2022 (Actual)
Study Completion Date
April 10, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sadat City University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the current study is to evaluate the safety and efficacy of Montelukast in treatment of obese patients with type 2 diabetes (T2DM).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity; Endocrine; Diabetes Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
50 patients will receive metformin up to 2000mg/daily (Control group)
Arm Title
Montelukast group
Arm Type
Experimental
Arm Description
50 patients will receive a combination of metformin up to 2000 mg/daily and montelukast (10 mg /day).
Intervention Type
Drug
Intervention Name(s)
Montelukast 10mg
Intervention Description
Montelukast is an orally dosed drug (available as a chewable tablet) which is FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo tablet once daily
Primary Outcome Measure Information:
Title
Change in HbA1c
Description
HbA1c
Time Frame
From baseline to 12 weeks
Title
Percent change in body weight
Description
Body Weight
Time Frame
From baseline to 12 weeks
Title
BMI
Description
body mass index
Time Frame
From baseline to 12 weeks
Title
Visceral Adiposity Index
Description
visceral fat
Time Frame
From baseline to 12 weeks
Secondary Outcome Measure Information:
Title
Adiponectin
Description
Serum level of adiponectin
Time Frame
At baseline to 12 weeks
Title
TNF-α
Description
Serum level of Tumor necrosis factor alpha (TNF-α)
Time Frame
At baseline to 12 weeks
Title
IL-6
Description
Serum level of interleukin-6 (IL-6)
Time Frame
At baseline to 12 weeks
Title
leukotriene B4
Description
Serum level of leukotriene B4 (LTB4)
Time Frame
At baseline to 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
- type 2 diabetic patients who had body mass index (BMI) ≥ 30 kg/m2 , were treated with metformin alone and had ages ranging from 18 to 60 years.
Exclusion Criteria:
patients who had any other inflammatory disease
patients with cardiovascular,
patients with asthma
patients with severe hepatic
patients with renal disease,
patients with epilepsy
pregnant or lactating females.
Facility Information:
Facility Name
Faculty of Medicine
City
Shebin Elkom
Country
Egypt
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs